2 5ml serum sample for proteine S100Beta and copeptine analysis

Seizures

S-100b Protein

Copeptin

Hopital Lariboisiere

Groupe Hospitalier pitie-salpetriere

Hopital Tenon

Royal London Hospital, Barts Health NHS Trust

Biomarkers In Seizure To Predict Recurrence and Severe Outcomes

Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department

number of days out of hospital, death corresponding to 0

Yonathan Freund

Chef de Clinique - Research fellow. MD

Bistro Study Group

Groupe Hospitalier Pitie-Salpetriere

Barts & The London NHS Trust

[ L + P ] = lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes) + placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

[ C + P ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + placebo 20 mg/kg by intravenous infusion over a period of 2 15 minutes

[ C + F ] = clonazepam 0,015 mg/kg by intravenous injection over a period of 2 to 3 minutes + fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Status Epilepticus

Epilepsy

Clonazepam

fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes

Fosphenytoin

placebo 20 mg/kg by intravenous infusion over a period of 15 minutes

Placebo

lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)

Lorazepam

Département d'Anesthésie - Réanimation - SMUR - Hôpital Lariboisière

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus

Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients

Percentage of patient with a cessation of seizures and absence of recurrence from 20 minutes until 60 minutes after the beginning of the treatment

Duration between the first cessation and the recurrence of seizures

Percentage of patients having had a second injection of benzodiazepine

Percentage of patients having had an injection of the second line treatment (i.e. Fosphenytoin or barbiturate)

Percentage of patients having a general anesthesia for refractory status epilepticus

Percentage of patients having had a side effect (low blood pressure, arrhythmias)

Percentage of patients having been mechanically ventilated in pre-hospital setting

Glasgow Coma Scale on arrival at the hospital

Mortality in hospital until J30 (if the patient still hospitalized)

Assistance Publique - Hôpitaux de Paris

Childhood Absence Epilepsy [Pyknolepsy]

Study of memory using MRI

Service Hospitalier Frédéric Joliot (SHFJ)

Necker Hospital

Functional Magnetic Resonance Imaging (fMRI) Study of Memory in Children

Anatomical and Functional MRI Study of Episodic Memory in Epileptic Compared to Normal Children

Yannick VACHER

Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level <30ng/ml) Cholecalciferol. 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 6 months

Drug resistant epilepsy patients with proved Vitamin D deficiency (Serum vitamin D level<30ng/ml) Placebo than cholecalciferol. 5 doses of placebo in 3 months than 5 doses of cholecalciferol (100 000 IU) in 3 months than 1 dose of cholecalciferol (100 000 IU) per month during 3 months.

Drug Resistant Epilepsy

Cholecalciferol

Placebo Oral

Vitamine D in Drug Resistant Epilepsy

Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy

Total score at baseline and after Vitamin D treatment (range 0-200; higher values=worse outcome)

Total score at baseline and after Vitamin D treatment (range 0-42; higher values=worse outcome)

Global score at baseline and after Vitamin D treatment (the higher score, the better outcome)

Vitamin D levels and percentage reduction in the seizure frequency compared to the reference period

Vitamin D level and type of AED (enzyme inducer versus non enzyme inducer drugs)

Vitamin D level and dose of AED (low dose versus high dose of enzyme inducer drugs)

Responder rate after Vitamin D treatment. Percentage of patients having a reduction of at least 50% of the seizure frequency

Percentage of patients without any seizure (seizure freedom)

Responder rate in focal and generalized epilepsy

Percentage of reduction of secondary generalized seizures and epileptic falls in respect to the reference period

Centre Hospitalier St Anne

APHP

FFRE

LFCE

The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients without intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.

The investigators will measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients with intradialytic hypotension and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.

Hemodialysis Complication

The additional examination, related to this research protocol, corresponds to a record of cutaneous conductance with chlorine. This recording of 2 min 30 is done thanks to SUDOSCAN® within 30 minutes before the dialysis session (before the "connection" to the dialysis machine) and within 30 minutes after the end of the dialysis with a measurement of the tension blood pressure and heart rate immediately before SUDOSCAN®.

Cutaneous conductance to chlorine by SUDOSCAN

AURA Paris Plaisance

Study of Abnormalities of the Nervous System in the Occurrence of Intradialytic Arterial Hypotension

Study of Abnormalities of the Vegetative Nervous System in the Occurrence of Intradialytic Arterial Hypotension

This outcome is to measure cutaneous conductance to chlorine by SUDOSCAN, 30 minuts before hemodialysis.

This outcome is to measure cutaneous conductance to chlorine by SUDOSCAN, 30 minuts after hemodialysis.

Groupe Hospitalier Paris Saint Joseph

Patients will be classified into 2 groups according to the occurrence of intradialytic hypotension which is defined as a decrease in systolic blood pressure greater than 30 mmHg associated with clinical signs (cramps, abdominal pain, unconsciousness, convulsions). Group 1 corresponds to patients with intradialytic hypotension and group 2 corresponds to patients without intradialytic hypotension. This study aims to measure the cutaneous conductance to chlorine by SUDOSCAN® in all dialysis patients and to seek a link between the results of this examination and the occurrence of discomfort during hemodialysis sessions.

These units use the same electronic prescribing system, but had no counselling software

Impaired Renal Function

implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value

computer-assisted counselling about target drugs

hopital Charles Foix et Université Paris 6

Computer Prescribing System and Impaired Renal Function

Impact of a Counselling System Coupled With a Computer Prescribing System to Optimize the Use of the Drugs for Old Subjects Having Renal Function Impairment